Alnylam Pharmaceuticals Inc
XMUN:DUL
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
A
|
Alnylam Pharmaceuticals Inc
XMUN:DUL
|
US |
|
Relmada Therapeutics Inc
F:4E2
|
US |
|
M
|
Martin Marietta Materials Inc
BMV:MLM
|
US |
|
M
|
Mycronic AB (publ)
F:MLT
|
SE |
|
T
|
Tractor Supply Co
F:TR4
|
US |
|
A
|
Agnico Eagle Mines Ltd
XMUN:AE9
|
CA |
|
C
|
China Merchants Port Holdings Co Ltd
F:CPM
|
HK |
|
Svenska Cellulosa SCA AB
F:SCA
|
SE |
|
X
|
Xcel Energy Inc
XMUN:NRN
|
US |
|
D
|
Darden Restaurants Inc
XMUN:DDN
|
US |
|
R
|
Ross Stores Inc
XMUN:RSO
|
US |
|
Standard Bank Group Ltd
F:SKC2
|
ZA |
|
SGS SA
OTC:SGSOF
|
CH |
|
MaxCyte Inc
LSE:MXCT
|
US |
|
E
|
Evolution AB (publ)
F:E3G
|
SE |
|
P
|
Paychex Inc
XMUN:PCX
|
US |
|
I
|
Inspire Medical Systems Inc
F:2DR
|
US |
Bankruptcy Probability
Alnylam Pharmaceuticals Inc's probability of bankruptcy is Hidden . The solvency score is Hidden .
We take all the information about a company's solvency, such as how easily it can pay interest on outstanding debt, how much cash it has, the amount of debt, and more, and use it to estimate the probability of bankruptcy.
Solvency Ratios
Solvency Ratios Comparison
Alnylam Pharmaceuticals Inc Competitors
| Country | Company | Market Cap | D/E | D/A |
Interest Coverage |
Altman Z-Score |
Quick Ratio |
Current Ratio |
Cash Ratio |
||
|---|---|---|---|---|---|---|---|---|---|---|---|
| US |
|
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
|
40.2B USD |
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
|
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR |
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
|
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD |
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
|
| US |
|
Abbvie Inc
NYSE:ABBV
|
364.4B USD |
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
|
| US |
|
Amgen Inc
NASDAQ:AMGN
|
178B USD |
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
|
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
165.6B USD |
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
|
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
107.9B USD |
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
|
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
74.2B USD |
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
|
| NL |
|
argenx SE
XBRU:ARGX
|
42B EUR |
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
|
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR |
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
|
| AU |
|
CSL Ltd
ASX:CSL
|
60B AUD |
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Alnylam Pharmaceuticals Inc's probability of bankruptcy is Hidden .
The probability of bankruptcy is estimated using credit risk models that assess financial health, debt levels, interest coverage, and other solvency indicators.
As of the latest report, Alnylam Pharmaceuticals Inc has total debt of 2.5B USD. This includes both short-term (0 USD) and long-term (2.5B USD) debt.
You can find a full breakdown on its Balance Sheet.
